HYDAMTIQ, a selective PARP‐1 inhibitor, improves bleomycin‐induced lung fibrosis by dampening the TGF‐β/SMAD signalling pathway

Abstract

Idiopathic pulmonary fibrosis is a severe disease characterized by excessive myofibroblast proliferation, extracellular matrix and fibrils deposition, remodelling of lung parenchyma and pulmonary insufficiency. Drugs able to reduce disease progression are available, but therapeutic results are unsatisfactory; new and safe treatments are urgently needed… (More)
DOI: 10.1111/jcmm.12967

Topics

6 Figures and Tables

Cite this paper

@inproceedings{Lucarini2017HA, title={ HYDAMTIQ, a selective PARP‐1 inhibitor, improves bleomycin‐induced lung fibrosis by dampening the TGF‐β/SMAD signalling pathway}, author={Laura Lucarini and Mariaconcetta Durante and Cecilia Rodr{\'i}guez Lanzi and Alessandro Pini and Giulia Boccalini and Laura Calosi and Flavio Moroni and Emanuela Masini and Guido Mannaioni}, booktitle={Journal of cellular and molecular medicine}, year={2017} }